Alnylam Releases New Data from Failed Phase IIb Study of RSV Drug | GenomeWeb

Alnylam Pharmaceuticals this week released the complete results from a phase IIb study of its respiratory syncytial virus drug ALN-RSV01, roughly three months after the company confirmed that the trial failed to meet its primary endpoint.

The company said that it still plans to meet with US and European regulators about the data, and that it aims to make a final decision by year end on whether development of the drug will continue.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.